Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses.
Many tumours express tumour-specific antigens capable of being presented to CD8+ T cells by major histocompatibility complex (MHC) class I molecules. Current models of antigen presentation predict that the tumour cell itself should present its own MHC class I-restricted antigens to T cells. Earlier cross-priming experiments have demonstrated that at least some MHC class I-restricted antigens may also be presented by bystander cells. There is no detectable presentation of MHC class I-restricted tumour antigens by the tumour itself during priming of tumour-specific responses. The tumour antigens are presented exclusively by host bone marrow-derived cells. These results imply that an efficient mechanism exists in vivo for transfer of MHC I-restricted antigens to bone marrow-derived antigen presenting cells. They also suggest that HLA matching may not be critical in the clinical application of allogeneic tumour vaccines.
Huang
A Y
AY
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Golumbek
P
P
Ahmadzadeh
M
M
Jaffee
E
E
Pardoll
D
D
Levitsky
H
H
D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis*; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology*; D001854:Bone Marrow Cells; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D051379:Mice
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D015395:Histocompatibility Antigens Class I